Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ULC004
MIFTS: 80

Ulcerative Colitis

Categories: Blood diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ulcerative Colitis

About this section

MalaCards integrated aliases for Ulcerative Colitis:

Name: Ulcerative Colitis 39 12 77 26 38 44 3 15 17 74
Inflammatory Bowel Disease, Ulcerative Colitis Type 26
Chronic Left-Sided Ulcerative Colitis 74
Left-Sided Ulcerative Colitis 12
Left Sided Ulcerative Colitis 74
Idiopathic Proctocolitis 26
Colitis, Ulcerative 45
Colitis Ulcerative 56
Colitis Gravis 26
Uc 26

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:8577
KEGG 38 H01466
ICD9CM 36 556 556.5 556.9
MeSH 45 D003093
NCIt 51 C2952
ICD10 34 K51 K51.9
Sources

Summaries for Ulcerative Colitis

About this section
MedlinePlus : 44 Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Ulcerative Colitis, also known as inflammatory bowel disease, ulcerative colitis type, is related to pyoderma gangrenosum and colonic disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Ulcerative Colitis is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include Bone, colon and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A colitis that is predominantly confined to the mucosa located in colon and includes characteristic ulcers, or open sores.

Genetics Home Reference : 26 Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectum and colon, which make up most of the length of the large intestine. The inflammation usually causes open sores (ulcers) to develop in the large intestine. Ulcerative colitis usually appears between ages 15 and 30, although it can develop at any age. The inflammation tends to flare up multiple times throughout life, which causes recurring signs and symptoms.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

Wikipedia : 77 Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon... more...

Sources

Related Diseases for Ulcerative Colitis

About this section

Diseases related to Ulcerative Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 863)
# Related Disease Score Top Affiliating Genes
1 pyoderma gangrenosum 33.1 CXCL8 NOD2 TNF
2 colonic disease 33.0 MLH1 MSH2 NOD2
3 pouchitis 32.9 CXCL8 IL10 NOD2 TLR4
4 inflammatory bowel disease 31.9 ABCB1 ATG16L1 CRP CXCL8 IL10 IL1B
5 pyoderma 31.8 CXCL8 NOD2 TNF
6 cytomegalovirus infection 31.6 CXCL8 IL1B TNF
7 colitis 31.6 ABCB1 ATG16L1 CXCL8 IL10 IL1B IL2
8 crohn's disease 31.5 ABCB1 ATG16L1 CRP IL10 IL23R IRGM
9 crohn's colitis 31.5 CXCL8 IL1B IL2 NOD2 TNF
10 ileitis 31.3 MPO NOD2 TLR4 TNF
11 proctitis 31.2 CRP MPO TNF
12 bronchiolitis obliterans 31.1 CXCL8 IL10 TNF
13 arthritis 31.0 CXCL8 IL10 IL1B NOD2 TNF
14 uveitis 30.8 IL10 NOD2 TNF
15 myasthenia gravis 30.8 IL10 IL2 TNF
16 colorectal adenocarcinoma 30.8 MLH1 MSH2 MUC2
17 spondylitis 30.8 CRP IL23R NOD2 TNF
18 inflammatory bowel disease 5 30.7 ATG16L1 IL23R NOD2
19 spondyloarthropathy 1 30.7 CRP NOD2 TLR4 TNF
20 autoimmune disease 30.7 IL10 IL1B IL2 TNF
21 osteomyelitis 30.7 CXCL8 IL10 IL1B TNF
22 interstitial lung disease 30.6 CXCL8 IL10 IL1B TNF
23 pericarditis 30.6 CRP IL1B TNF
24 bronchiolitis 30.6 CRP CXCL8 IL10 TLR4 TNF
25 ileocolitis 30.6 MYO9B NOD2 TNF
26 lung disease 30.6 CXCL8 IL10 IL1B MPO TNF
27 sarcoidosis 1 30.5 IL1B IL2 NOD2 TNF
28 acute pancreatitis 30.5 CRP CXCL8 IL10 MPO
29 aspergillosis 30.5 IL10 TLR4 TNF
30 endomyocardial fibrosis 30.5 IL10 TNF
31 hematopoietic stem cell transplantation 30.5 IL10 IL2 TNF
32 extrinsic allergic alveolitis 30.5 CXCL8 IL10 IL1B MPO
33 autoimmune inner ear disease 30.4 MPO TNF
34 peptic ulcer disease 30.4 CXCL8 IL10 IL1B TNF
35 pneumonia 30.4 CRP CXCL8 IL10 IL1B MPO TLR4
36 obstructive jaundice 30.4 CRP CXCL8 TNF
37 familial mediterranean fever 30.4 CRP IL1B NOD2 TNF
38 human immunodeficiency virus infectious disease 30.4 IL10 IL2 TNF
39 appendicitis 30.3 CRP CXCL8 IL10 IL1B MPO TNF
40 meningitis 30.3 CRP CXCL8 IL10 IL1B TNF
41 duodenal ulcer 30.3 CXCL8 IL1B TNF
42 endocarditis 30.3 CRP CXCL8 IL10 TNF
43 spondylarthropathy 30.2 NOD2 TLR4 TNF
44 wells syndrome 30.2 CRP CXCL8 IL1B IL2
45 transverse myelitis 30.2 CXCL8 IL10 TNF
46 eales disease 30.2 IL10 IL1B TNF
47 tonsillitis 30.2 CXCL8 IL1B IL2 TNF
48 psoriatic arthritis 30.2 CRP IL1B IL23R NOD2 TNF
49 chronic fatigue syndrome 30.1 IL10 IL1B IL2 TNF
50 cystitis 30.1 CRP CXCL8 TLR4 TNF

Comorbidity relations with Ulcerative Colitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Obstruction
Iron Deficiency Anemia Paralytic Ileus
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ulcerative Colitis:



Diseases related to Ulcerative Colitis
Sources

Symptoms & Phenotypes for Ulcerative Colitis

About this section

UMLS symptoms related to Ulcerative Colitis:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CXCL8 IL10 IL1B IL2 MLH1 MPO
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CXCL8 IL10 IL1B IL2 MLH1 MPO
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.8 NOD2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.8 CRP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.8 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.8 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.8 CRP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.8 TLR4
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.8 IL10
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.8 IL10
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.8 CRP IL10 NOD2 TLR4
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.8 NOD2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.8 CRP

MGI Mouse Phenotypes related to Ulcerative Colitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 ABCB1 ATG16L1 IL10 IL1B IL2 IL23R
2 cardiovascular system MP:0005385 10.07 ABCB1 ATG16L1 CRP IL10 IL1B IL2
3 digestive/alimentary MP:0005381 10.06 ABCB1 ATG16L1 IL10 IL2 IL23R MLH1
4 homeostasis/metabolism MP:0005376 10 ABCB1 ATG16L1 CRP IL10 IL1B IL2
5 immune system MP:0005387 9.83 ABCB1 ATG16L1 CRP IL10 IL1B IL2
6 neoplasm MP:0002006 9.28 IL10 IL1B IL2 IL23R MLH1 MSH2
Sources

Drugs & Therapeutics for Ulcerative Colitis

About this section

Drugs for Ulcerative Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 362)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
2
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
4
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
5
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
6
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
7
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6, 15438-31-0 27284 23925
8
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
9
Copper Approved, Investigational Phase 4 7440-50-8 27099
10
Tocopherol Approved, Investigational Phase 4,Phase 2,Not Applicable 1406-66-2 14986
11
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
12
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
13 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 943609-66-3
14
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
16
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
18
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
20
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
22
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
23
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 6473866 445643 439492
24
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-44-2 667490
25
Linaclotide Approved Phase 4 851199-59-2 65351
26
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
27
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 443-48-1 4173
28
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
29
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
30
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 1 477600-75-2
31
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
32
carbamide peroxide Approved Phase 4 124-43-6
33
Methotrexate Approved Phase 4,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
34
Vancomycin Approved Phase 4,Phase 2,Phase 1,Not Applicable 1404-90-6 14969 441141
35
Certolizumab pegol Approved Phase 4,Phase 2 428863-50-7
36
Ustekinumab Approved, Investigational Phase 4,Phase 3 815610-63-0
37
Sodium Citrate Approved, Investigational Phase 4,Not Applicable 68-04-2
38
Magnesium citrate Approved Phase 4 3344-18-1
39
Losartan Approved Phase 4 114798-26-4 3961
40
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
41
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
42
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696
43
Caffeine Approved Phase 4 58-08-2 2519
44
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
45
Vitamin C Approved, Nutraceutical Phase 4,Not Applicable 50-81-7 54670067 5785
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 59-30-3 6037
47
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 59-02-9 14985
48
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
49
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
50 Tocotrienol Investigational Phase 4,Phase 2,Not Applicable 6829-55-6

Interventional clinical trials:

(show top 50) (show all 1084)
# Name Status NCT ID Phase Drugs
1 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
2 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
3 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
4 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
5 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
6 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
7 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
8 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
9 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
10 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
11 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
12 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
13 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
14 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
15 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
16 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
17 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
18 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
19 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4 Infliximab
20 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4 Golimumab
21 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
22 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
23 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
24 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4 Mesalamine
25 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
26 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
27 Adacolumn in Refractory UC Patients Trial Completed NCT01481142 Phase 4
28 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4 mesalamine
29 Predicting Response to Standardized Pediatric Colitis Therapy Completed NCT01536535 Phase 4 Mesalamine;Corticosteroid;Corticosteroids then mesalamine
30 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
31 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed NCT02559713 Phase 4 Vedolizumab
32 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed NCT02318667 Phase 4
33 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
34 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
35 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
36 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
37 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
38 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
39 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
40 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
41 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
42 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
43 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
44 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
45 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
46 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
47 Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Recruiting NCT02345733 Phase 4 Antibiotic cocktail
48 A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission Recruiting NCT03281304 Phase 4 CP-690,500 5 mg;CP-690,550 10 mg
49 Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis Recruiting NCT02770040 Phase 4 Infliximab
50 Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis Recruiting NCT02921555 Phase 4 Methylprednisolone;Prednisone

Search NIH Clinical Center for Ulcerative Colitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ulcerative Colitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Ulcerative Colitis:
MultiStem, bone marrow-derived cells for inflammatory bowel diseases
Regenerative ColoTherapy, stem cells for inflammatory bowel diseases
Embryonic/Adult Cultured Cells Related to Ulcerative Colitis:
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285
Adipose-derived mesenchymal stem cells (family)
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: colitis, ulcerative

Sources

Genetic Tests for Ulcerative Colitis

About this section
Sources

Anatomical Context for Ulcerative Colitis

About this section

MalaCards organs/tissues related to Ulcerative Colitis:

42
Colon, Testes, T Cells, Neutrophil, Skin, Kidney, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Ulcerative Colitis:

20
Colon
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ulcerative Colitis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
Sources

Publications for Ulcerative Colitis

About this section

Articles related to Ulcerative Colitis:

(show top 50) (show all 6129)
# Title Authors Year
1
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? ( 30920041 )
2019
2
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. ( 30920043 )
2019
3
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. ( 30920048 )
2019
4
Bowel-associated dermatosis arthritis syndrome and palisading neutrophilic granulomatous dermatitis as presentation of ulcerative colitis. ( 30924626 )
2019
5
Sequelae of breast pyoderma gangrenosum associated with ulcerative colitis: Impact on breast cancer screening. ( 31077481 )
2019
6
Infliximab-induced bullous pemphigoid and anti-desmoglein 3 and anti-BP180 autoantibodies in a patient with ulcerative colitis. ( 30530408 )
2019
7
Oral Vancomycin Induces and Maintains Remission of Ulcerative Colitis in the Subset of Patients With Associated Primary Sclerosing Cholangitis. ( 30838381 )
2019
8
Sarcoidosis of the Intra- and Extrahepatic Bile Ducts with Concomitant Cholangitis in a Patient with Ulcerative Colitis. ( 31097931 )
2019
9
High Serum sCD40 and a Distinct Colonic T Cell Profile in Ulcerative Colitis Associated With Primary Sclerosing Cholangitis. ( 30383225 )
2019
10
Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening. ( 30852608 )
2019
11
Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes? ( 31078249 )
2019
12
Strictures in Crohn's Disease and Ulcerative Colitis: Is There a Role for the Gastroenterologist or Do We Always Need a Surgeon? ( 31078252 )
2019
13
Recurrent Inflammatory Myositis as an Extra-Intestinal Manifestation of Dormant Ulcerative Colitis in a Patient on Long-Term Mesalamine. ( 31080678 )
2019
14
A rare case of bullous Sweet's Syndrome in a patient with inactive ulcerative colitis. ( 31081562 )
2019
15
Small bowel capsule endoscopy in ulcerative colitis: the capcolitis study: a prospective observational study. ( 31082999 )
2019
16
Huangkui Lianchang Decoction Ameliorates DSS-Induced Ulcerative Colitis in Mice by Inhibiting the NF-kappaB Signaling Pathway. ( 31093294 )
2019
17
Dose-response relationship between cigarette smoking and risk of ulcerative colitis: a nationwide population-based study. ( 31093771 )
2019
18
Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates. ( 31093812 )
2019
19
The Writing Is on the Wall: The Utility of Mural Stratification for Risk Stratification of Hospitalized Patients with Severe Ulcerative Colitis. ( 31093813 )
2019
20
Celiac disease associated with ulcerative colitis. ( 31094177 )
2019
21
Markers of dysbiosis in patients with ulcerative colitis and Crohn's disease. ( 31094471 )
2019
22
Performance of a Deep Learning Model vs Human Reviewers in Grading Endoscopic Disease Severity of Patients With Ulcerative Colitis. ( 31099869 )
2019
23
Efficacy of tofacitinib treatment in ulcerative colitis. ( 31101342 )
2019
24
Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. ( 31102012 )
2019
25
Qing Chang Hua Shi granule ameliorate inflammation in experimental rats and cell model of ulcerative colitis through MEK/ERK signaling pathway. ( 31102937 )
2019
26
Regulating effect of baicalin on IKK/IKB/NF-kB signaling pathway and apoptosis-related proteins in rats with ulcerative colitis. ( 31103874 )
2019
27
Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. ( 31103945 )
2019
28
Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. ( 31106602 )
2019
29
Outcome Comparison of Single-port Versus Multiport Versus Under Direct View Completion Proctectomy With Ileal-Pouch Anal Anastomosis for Patients With Ulcerative Colitis. ( 31107848 )
2019
30
Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials. ( 31108227 )
2019
31
Subclinical Nasal and Lung Lymphocytosis in Ulcerative Colitis. ( 31111035 )
2019
32
Perspectives of cytomegalovirus infection in ulcerative colitis. ( 31111828 )
2019
33
A case of screening colonoscopy using linked-color imaging to detect ulcerative colitis-associated colorectal cancer. ( 31000480 )
2019
34
Aberrant Brain Function in Active-Stage Ulcerative Colitis Patients: A Resting-State Functional MRI Study. ( 31001097 )
2019
35
Multiple Epistasis Interactions Within MHC Are Associated With Ulcerative Colitis. ( 31001315 )
2019
36
Impact of Changing Treatment Strategies on Outcomes in Pediatric Ulcerative Colitis. ( 31002341 )
2019
37
Risk Factors of Colectomy in Patients With Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab. ( 31003696 )
2019
38
Rapid Onset of Tofacitinib Induction Therapy for the Treatment of Ulcerative Colitis. ( 31003697 )
2019
39
Extracellular vesicles derived from bone marrow mesenchymal stem cells attenuate dextran sodium sulfate-induced ulcerative colitis by promoting M2 macrophage polarization. ( 31005036 )
2019
40
Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis. ( 31009805 )
2019
41
An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. ( 31012362 )
2019
42
Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis. ( 31016561 )
2019
43
Histologic Remission in Ulcerative Colitis: Are We There Yet? ( 31021831 )
2019
44
Acoustic radiation force impulse (ARFI) shear wave elastography of the bowel wall in healthy volunteers and in ulcerative colitis. ( 31024741 )
2019
45
Management of elderly ulcerative colitis in Japan. ( 31025187 )
2019
46
Efficacy and Safety of Adsorptive Granulocyte and Monocyte Apheresis in Elderly and Pregnant Patients with Ulcerative Colitis. ( 31025815 )
2019
47
Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis is Suitable for Elderly Patients with Active Ulcerative Colitis Patients Taking No Corticosteroids or Biologics. ( 31025824 )
2019
48
Dietary Factors in Sulfur Metabolism and Pathogenesis of Ulcerative Colitis. ( 31027194 )
2019
49
Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis. ( 31030460 )
2019
50
Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. ( 31033520 )
2019
Sources

Variations for Ulcerative Colitis

About this section
Sources

Expression for Ulcerative Colitis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Ulcerative Colitis patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CLDN8 claudin 8 Colon - 4.72 0.000
2 LCN2 lipocalin 2 Colon + 4.60 0.000
3 REG3A regenerating islet-derived 3 alpha Colon + 4.41 0.001
4 SLC26A2 solute carrier family 26 (anion exchanger), member 2 Colon - 4.19 0.000
5 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) Colon - 4.13 0.000
6 CXCL8 chemokine (C-X-C motif) ligand 8 Colon + 3.86 0.003
7 CXCL2 chemokine (C-X-C motif) ligand 2 Colon + 3.85 0.000
8 REG1A regenerating islet-derived 1 alpha Colon + 3.68 0.005
9 RGS3 regulator of G-protein signaling 3 Colon + 3.58 0.000
10 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Colon + 3.55 0.000
11 OLFM4 olfactomedin 4 Colon + 3.25 0.014
12 DEFA6 defensin, alpha 6, Paneth cell-specific Colon + 3.22 0.003
Search GEO for disease gene expression data for Ulcerative Colitis.
Sources

Pathways for Ulcerative Colitis

About this section

Pathways related to Ulcerative Colitis according to KEGG:

38
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630
3 Inflammatory bowel disease (IBD) hsa05321

Pathways related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.03 CRP CXCL8 IL10 IL1B IL2 IL23R
2
Cytokine Signaling in Immune system 67
Show member pathways
 13.35 CXCL8 IL10 IL1B IL2 IL23R NOD2
3
PAK Pathway 65
Show member pathways
 13.3 CXCL8 IL10 IL1B IL2 IL23R MYO9B
4
Toll-like Receptor Signaling Pathway 1 38
Show member pathways
 13.03 ATG16L1 CXCL8 IL10 IL1B IL2 NOD2
5
Allograft rejection 38 1
Show member pathways
 12.87 ABCB1 CXCL8 IL10 IL1B IL2 TNF
6
Pathways in cancer 38
12.82 CXCL8 IL2 IL23R MLH1 MSH2
7
NF-kappaB Signaling 4
12.56 IL10 IL1B IL2 MPO TNF
8
T cell receptor signaling pathway 38
Show member pathways
 12.54 IL10 IL1B IL2 TNF
9
Th17 cell differentiation 38
Show member pathways
 12.49 IL10 IL1B IL2 IL23R NOD2 TLR4
10
Immune response IL-23 signaling pathway 23
Show member pathways
 12.45 IL10 IL1B IL2 IL23R MPO MSH2
11
Selenium Micronutrient Network 1
Show member pathways
 12.34 CRP IL1B IL2 MPO TNF
12
Toll Comparative Pathway 65
Show member pathways
 12.29 CXCL8 IL1B TLR4 TNF
13
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.26 CXCL8 IL10 IL1B IL2 TNF
14
Toxoplasmosis 38
Show member pathways
 12.26 IL10 IL1B IRGM TLR4 TNF
15
IL-1 Family Signaling Pathways 66
Show member pathways
 12.23 CXCL8 IL1B MUC2 TNF
16
C-type lectin receptor signaling pathway 38
Show member pathways
 12.22 IL10 IL1B IL2 TNF
17
Tuberculosis 38
12.21 IL10 IL1B NOD2 TLR4 TNF
18
Bacterial infections in CF airways 23
Show member pathways
 12.19 CXCL8 IL1B TLR4 TNF
19
Colorectal Cancer Metastasis 65
12.19 MLH1 MSH2 TLR4 TNF
20
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.18 CXCL8 IL10 IL1B TNF
21
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12 IL10 IL2 MPO TNF
22
Spinal Cord Injury 1
11.99 CXCL8 IL1B IL2 TLR4 TNF
23
Interleukin-4 and 13 signaling 67
11.93 CXCL8 IL10 IL1B IL23R TNF
24
NF-kappa B signaling pathway 38
11.92 CXCL8 IL1B TLR4 TNF
25
Rheumatoid arthritis 38
11.88 CXCL8 IL1B TLR4 TNF
26
Corticotropin-releasing hormone signaling pathway 1
11.85 CXCL8 IL2 TLR4
27
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.85 CXCL8 IL23R TLR4
28
Salmonella infection (KEGG) 38
11.81 CXCL8 IL1B TLR4
29
Dendritic Cells Developmental Lineage Pathway